Biogen tanks as opicinumab misses Phase II endpoints in MS trial
Biogen reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being ...
Biogen reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being ...
Indianapolis-based pharmaceutical giant Eli Lilly LLY -0.64% laid out an ambitious R&D agenda for launching up to 20 new drugs ...
Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in ...
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival ...
AbbVie will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and ...
Almac Group, the global contract development and manufacturing organisation, is pleased to announce an expansion to its serialisation capabilities to ...
Will Represent Sixth U.S. Patent to Be Listed in the Orange Book for RAVICTI Horizon Pharma plc (NASDAQ: HZNP), a ...
Alcon’s limited unilateral pricing policy applies only to new and innovative brands of contact lens and was introduced to encourage ...
AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in ...
Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK), ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.